Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 and SMO Mutated Tumors
Phase of Trial: Phase II
Latest Information Update: 05 May 2016
Price : $35 *
At a glance
- Drugs Sonidegib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis
- 25 Apr 2016 Status changed from completed to discontinued.
- 24 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinialTrials.gov record.
- 18 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.